Advances in prostate cancer chemotherapy: A new era begins

被引:142
作者
Pienta, KJ [1 ]
Smith, DC
机构
[1] Univ Michigan, Michigan Urol Ctr, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Multidisciplinary Urol Oncol Clin, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
关键词
D O I
10.3322/canjclin.55.5.300
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer continues to be the most common lethal malignancy diagnosed in American men and the second leading cause of male cancer mortality. Over 60 years ago, Huggins and Hodges discovered androgen deprivation as a first-line therapy for metastatic prostate cancer, which leads to remissions typically lasting 2 to 3 years, but in most men prostate cancer ultimately progresses to an androgen-independent state resulting in death due to widespread metastases. Multiple mechanisms of androgen independence have now been documented, including amplification of the androgen receptor as well as signal transduction pathways that bypass the androgen receptor completely. In 2004, two landmark studies demonstrated a survival advantage in androgen-independent prostate cancer patients utilizing docetaxel chemotherapy, setting a new standard of care for this disease. In addition, treatments with the bisphosphonate zoledronic acid and systemic radioisotopes have also been shown to have palliative benefits in this population. Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development.
引用
收藏
页码:300 / 318
页数:19
相关论文
共 115 条
[1]   Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression [J].
Aass, N ;
Fosså, SD .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) :259-265
[2]   A multi institutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone [J].
Akerley, W ;
Butera, J ;
Wehbe, T ;
Noto, R ;
Stein, B ;
Safran, H ;
Cummings, F ;
Sambandam, S ;
Maynard, J ;
De Rienzo, G ;
Leone, L .
CANCER, 2002, 94 (06) :1654-1660
[3]   Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].
Bander, NH ;
Nanus, DM ;
Milowsky, MI ;
Kostakoglu, L ;
Vallabahajosula, S ;
Goldsmith, SJ .
SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677
[4]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[5]  
Beer T, 2000, PROSTATE, V45, P184, DOI 10.1002/1097-0045(20001001)45:2<184::AID-PROS13>3.0.CO
[6]  
2-K
[7]   Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer [J].
Beer, TM ;
Pierce, WC ;
Lowe, BA ;
Henner, WD .
ANNALS OF ONCOLOGY, 2001, 12 (09) :1273-1279
[8]   Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate [J].
Berry, W ;
Dakhil, S ;
Gregurich, MA ;
Asmar, L .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :8-15
[9]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[10]   Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].
Bubley, GJ ;
Carducci, M ;
Dahut, W ;
Dawson, N ;
Daliani, D ;
Eisenberger, M ;
Figg, WD ;
Freidlin, B ;
Halabi, S ;
Hudes, G ;
Hussain, M ;
Kaplan, R ;
Myers, C ;
Oh, W ;
Petrylak, DP ;
Reed, E ;
Roth, B ;
Sartor, O ;
Scher, H ;
Simons, J ;
Sinibaldi, V ;
Small, EJ ;
Smith, MR ;
Trump, DL ;
Vollmer, R ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467